Emmy Award winner, ‘Fame’ star Debbie Allen joins NKF to assist detect, handle diabetes

0
533

March 09, 2021

2 min read

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Emmy Award and Golden Globe winner Debbie Allen works with the National Kidney Foundation on an education campaign to help people with type 2 diabetes reduce their risk of developing chronic kidney disease.

Allen, a producer, director, and choreographer known for her role on the television series “Fame” and her skills as a professional dancer, has a family history of diabetes and was recently diagnosed with pre-diabetes.

“Despite all of my years of dancing and careful diet to reduce the risk of type 2 diabetes, I was recently diagnosed with pre-diabetes,” Allen said in a press release. “From my father, grandfather, aunts and uncle, this disease shaped my family, so I know that it puts me at an increased risk of chronic kidney disease.”

Debbie Allen

Debbie Allen

She joins the NKF. “Are you the 33%?” Campaign as a prominent speaker during National Kidney Month and in honor of World Kidney Day on March 11th. On that day, everyone will have a virtual fireside chat to discuss their family relationship with diabetes.

“Are you the 33%?” focuses on the relationship between type 2 diabetes and CKD. The campaign, which began in March 2020, says one in three people nationwide are at risk for CKD.

People can take a 1-minute quiz on MinuteForYourKidneys.org for more information about their condition, the NKF said.

“At 33 [%] Of all adults in the United States who are at risk of developing kidney disease, it is like one in three dancers, like Debbie Allen, being at risk in a performance. ” Joseph Vassalotti, MD, Chief Physician of the NKF said. “We urgently need to transform understanding of the risk into action to protect kidney health.”

The NKF partnered with Bayer Medical when it launched its kidney health campaign last year. Bayer reported results from Phase 3 of the FIDELIO (Diabetic Kidney Disease) DKD study last fall, which showed the drug finerenone to delay the progression of CKD and reduce the risk of cardiovascular events in patients with type 2 diabetes decreased.

Bayer is also conducting the FIGARO-DKD study, which examines the efficacy and safety of finerenone versus placebo in reducing cardiovascular morbidity and mortality in approximately 7,400 patients with CKD and type 2 diabetes in 47 countries.

In January Bayer received FDA priority review for finerenone for the treatment of patients with CKD and type 2 diabetes.

“We have been committed” over the past 6 to 7 years to finding ways to treat diabetic kidney disease. Amit Sharma, MD, FASN, The vice president of medical affairs, cardiovascular and kidney departments at Bayer told Healio Nephrology. “There was no innovation [in treating diabetic kidney disease] in 25 years. “The Figero study focuses on both kidney and heart protection,” Sharma said.

Vassalotti told Healio Nephrology that the development of new drugs will enable nephrologists to provide both heart and kidney protection to patients like Allen, who are in the early stages of diabetes.

“Think about the public health challenge [type 2 diabetes] T2D, ”said Vassalotti. “The best chance of preventing T2D kidney disease in this population is with these new kidney and cardioprotective drugs.

“Nephrologists always said they only had one tool. Now we have an opportunity to slow the progression of kidney disease and make it cardioprotective, ”he said.

Reference:

www.healio.com/news/nephrology/20201024/finerenone-effective-in-reducing-cardiac-eskd-risk-in-patients-with-diabetes

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio